Charlie Kim


"Authentic Big Law" –
Can we practice law at the very highest levels, while also in a personal, caring and team-focused way that rejects discrimination and self-promotion at the cost of others, and truly reflects the ideals we hold onto so dearly outside of work? We here at Team Cooley answer that question with a resounding "yes!"

Charlie Kim is co-chair of Cooley's global capital markets practice group. He is a nationwide leader in capital markets transactions and has worked on 100+ successfully completed public company securities offerings since 2020 (including Uber's $8.1 billion IPO). Charlie focuses on representing US and non-US issuers, investment banking firms and venture capital firms in public offerings and private placements of equity and debt securities.

Download full bio 


  • Uber Technologies $8.1 Billion IPO 

  • Sweetgreen – $418.6 Million IPO 

  • 10X Genomics – $449 Million IPO  

  • Lyell Immunopharma – $425 Million IPO 

  • Sana Biotechnology - $676 million IPO 

  • View all

Charlie Kim skillfully navigating your capital markets transactions - priceless. Charlie's depth and breadth of knowledge/experience was crucial in the successful execution of our IPO and multiple follow-on offerings which tallied to over $1.2 billion. Internally, we nicknamed Charlie the 'Ironman of Capital Markets'. He and his team were a pleasure to partner with from the pre-planning phase all the way through the end of the process. – Tom Walker, former CFO of Tableau Software

  • New York University School of Law
    JD, McKay Scholar, 2000

  • Princeton Theological Seminary
    MDiv, Top 1% of Class, 1997

  • University of Michigan, Ann Arbor
    BA, Religious Studies
    Academic Distinction, 1994

Admissions & Credentials


New York


  • American Bar Association

  • New York State Bar Association

  • San Diego County Bar Association

Rankings & Accolades

    Daily Journal: California Lawyer Attorneys of the Year; Top 100 Lawyer in California

    Chambers USA: Capital Markets: Debt & Equity – Nationwide (Western United States) (Band 1)

    Law 360: Capital Markets MVP

    Legal 500: Leading Lawyer - Capital Markets: Equity Offerings; Next Generation Lawyer - Capital Markets: Equity Offerings

    Thomas Reuters: San Diego & Southern California Super Lawyer

    The Daily Transcript: San Diego Top Attorney

Representative Issuers

Charlie has represented companies/investment banks on capital market transactions involving issuers across industries, such as: AbCellera, Accelerate, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apigee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Biomea, Cadence, Castlight, Cerus, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood Therapeutics, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Insys, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry's, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Seattle Genetics, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, TRACON, Treace, Tricida, Trius, TriVascular Technologies, Uber Technologies, Vaxcyte, Ventyx Biosciences,, Verenium, Verona, Vical, ViewRay, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.